Kala Pharmaceuticals, Inc. announced the appointment of Mark Iwicki as Executive Chairman and a member of its board of directors. Mr. Iwicki will help guide corporate strategy and commercial preparations for Kala's lead product candidate, KPI-121, a novel nanoparticle formulation of loteprednol etabonate in development for the treatment of post-surgical ocular inflammation and pain and for dry eye and meibomian gland disease.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.53 USD | +0.31% | -2.96% | -6.71% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.71% | 18.34M | |
+39.51% | 723B | |
+34.28% | 595B | |
-3.65% | 369B | |
+20.35% | 332B | |
+2.88% | 282B | |
+17.15% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.02% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceuticals, Inc. Appoints Mark Iwicki as Executive Chairman and Member of Board of Directors